Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters11-13

<a href="https://laohu8.com/S/POAI">Predictive Oncology</a> Inc reports results for the quarter ended September 30 - Earnings Summary

Predictive Oncology Inc POAI.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter ended September 30. The lone analyst forecast for the quarter was for a loss of 32 cents per share.
Revenue was $346.00 thousand; analysts expected $500.00 thousand.
Predictive Oncology Inc's reported EPS for the quarter was a loss of 48 cents.
Predictive Oncology Inc shares had fallen by 0.1% this quarter and lost 76.1% so far this year.

FORECAST CHANGES

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Predictive Oncology Inc is $3.00

This summary was machine generated from LSEG data November 13 at 02:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING	ESTIMATE	ACTUAL	BEAT, MET, MISSED
Sep. 30 2024	-0.32	-0.48	Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483788637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-13 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483788637","market":"us","top_or_hot":-1,"title":"Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings Summary","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> Inc reports results for the quarter ended September 30 - Earnings Summary</title></head><body><ul><li><p>Predictive Oncology Inc <span>POAI.OQ</span> reported a quarterly adjusted loss of 48 cents per share for the quarter ended September 30.  The lone analyst forecast for the quarter was for a loss of 32 cents per share. </p></li><li><p>Revenue was $346.00 thousand; analysts expected $500.00 thousand. </p></li><li><p>Predictive Oncology Inc's reported EPS for the quarter was a loss of 48 cents.</p></li><li><p>Predictive Oncology Inc shares had fallen by 0.1% this quarter and lost 76.1% so far this year.</p></li></ul><p>FORECAST CHANGES</p><ul><li><p>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p></li></ul><p>RECOMMENDATIONS</p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" </p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is also \"buy\"</p></li></ul><p>Wall Street's median 12-month price target for Predictive Oncology Inc is $3.00 </p><p>This summary was machine generated from LSEG data November 13 at 02:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td></tr><tr><td><p>Sep. 30 2024 </p></td><td><p>-0.32</p></td><td><p>-0.48</p></td><td><p>Missed</p></td></tr></tbody></table></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPredictive Oncology Inc reports results for the quarter ended September 30 - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1JO:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings SummaryPredictive Oncology Inc POAI.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1JO:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"POAI","symbol_name":"Predictive Oncology","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1JO:1","article_id":"2483788637","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483788637","pubTimestamp":1731507462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings SummaryPredictive Oncology Inc POAI.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter en","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"POAI":"Predictive Oncology"},"translate_title":"Predictive Oncology Inc报告截至9月30日的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POAI":0.9},"content_text":"Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings SummaryPredictive Oncology Inc POAI.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter ended September 30.  The lone analyst forecast for the quarter was for a loss of 32 cents per share. Revenue was $346.00 thousand; analysts expected $500.00 thousand. Predictive Oncology Inc's reported EPS for the quarter was a loss of 48 cents.Predictive Oncology Inc shares had fallen by 0.1% this quarter and lost 76.1% so far this year.FORECAST CHANGESIn the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONSThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the medical equipment, supplies & distribution peer group is also \"buy\"Wall Street's median 12-month price target for Predictive Oncology Inc is $3.00 This summary was machine generated from LSEG data November 13 at 02:17 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)QUARTER ENDINGESTIMATE ACTUALBEAT, MET, MISSEDSep. 30 2024 -0.32-0.48Missed","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483788637"}